Compare ZSQR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZSQR | KROS |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 206.0M |
| IPO Year | 2020 | 2020 |
| Metric | ZSQR | KROS |
|---|---|---|
| Price | $3.91 | $11.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | ★ 375.9K | 148.6K |
| Earning Date | 08-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.27 | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | $1,363,045.00 | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $9.69 |
| 52 Week High | $16.62 | $22.55 |
| Indicator | ZSQR | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 52.16 |
| Support Level | $2.81 | $10.59 |
| Resistance Level | $4.64 | $11.69 |
| Average True Range (ATR) | 0.47 | 0.43 |
| MACD | 0.26 | -0.02 |
| Stochastic Oscillator | 79.36 | 48.15 |
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.